Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

References

• Kahn HA Leibowitz HM Ganley JP The Framingham Eye Study. I. Outline and major prevalence findings Am J Epidemiol 1977 106 17 32 879158
   PubMed Web of Science ®Google Scholar
• Klein R Klein BE Linton KL Prevalence of age-related maculopathy The Beaver Dam Eye Study Ophthalmology 1992 99 933 943 1630784
   PubMed Web of Science ®Google Scholar
• Klein BE Klein R Cataracts and macular degeneration in older Americans Arch Ophthalmol 1982 100 571 573 7073566
   PubMed Web of Science ®Google Scholar
• Mitchell P Smith W Attebo K Wang JJ Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study Ophthalmology 1995 102 1450 1460 9097791
   PubMed Web of Science ®Google Scholar
• Ferrara N Gerber HP Lecouter J The biology of VEGF and its receptors Nat Med 2003 9 669 676 12778165
   PubMed Web of Science ®Google Scholar
• Fine SL Berger JW Maguire MG Ho AC Age-related macular degeneration N Engl J Med 2000 342 483 492 10675430
   PubMed Web of Science ®Google Scholar
• Aiello LP Avery RL Arrigg PG Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 1994 331 1480 1487 7526212
   PubMed Web of Science ®Google Scholar
• Adamis AP Shima DT Tolentino MJ Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 1996 114 66 71 8540853
   PubMed Web of Science ®Google Scholar
• Presta LG Chen H O’Connor SJ Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 1997 57 4593 4599 9377574
   PubMed Web of Science ®Google Scholar
• Hurwitz H Fehrenbacher L Novotny W Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 350 2335 2342 15175435
   PubMed Web of Science ®Google Scholar
• Manoj SM Why does anti VEGF treatment fail in age related macular degeneration (AMD) Kerala Journal of Ophthalmology 2011
   Google Scholar
• Sho K Takahashi K Yamada H Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics Arch Ophthalmol 2003 121 1392 1396 14557174
   PubMedGoogle Scholar
• Cho M Barbazetto IA Freund KB Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy Am J Ophthalmol 2009 148 70 78 e1 19403115
   PubMed Web of Science ®Google Scholar
• Seddon JM Francis PJ George S Schultz DW Rosner B Klein ML Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration JAMA 2007 297 1793 1800 17456821
   PubMed Web of Science ®Google Scholar
• Chan WM Lam DS Lai TY Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series Ophthalmology 2004 111 1576 1584 15288991
   PubMed Web of Science ®Google Scholar
• Eandi CM Ober MD Freund KB Slakter JS Yannuzzi LA Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization Retina 2007 27 825 831 17891004
   PubMed Web of Science ®Google Scholar
• Wakabayashi T Gomi F Sawa M Tsujikawa M Tano Y Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy Br J Ophthalmol 2008 92 936 940 18577645
   PubMed Web of Science ®Google Scholar
• Gomi F Sawa M Sakaguchi H Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 2008 92 70 73 17567661
   PubMed Web of Science ®Google Scholar
• Koh AH Chen LJ Chen SJ Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment Retina 2013 33 686 716 23455233
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA Negrao S Iida T Retinal angiomatous proliferation in age-related macular degeneration Retina 2001 21 416 434 11642370
   PubMed Web of Science ®Google Scholar
• Freund KB Ho IV Barbazetto IA Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation Retina 2008 28 201 211 18301024
   PubMed Web of Science ®Google Scholar
• Scott AW Bressler SB Retinal angiomatous proliferation or retinal anastomosis to the lesion Eye (Lond) 2010 24 491 496 20019765
   PubMed Web of Science ®Google Scholar
• Cohen SY Creuzot-Garcher C Darmon J Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration Br J Ophthalmol 2007 91 1173 1176 17383997
   PubMed Web of Science ®Google Scholar
• Maruko I Iida T Saito M Nagayama D Saito K Clinical characteristics of exudative age-related macular degeneration in Japanese patients Am J Ophthalmol 2007 144 15 22 17509509
   PubMed Web of Science ®Google Scholar
• Hartnett ME Weiter JJ Staurenghi G Elsner AE Deep retinal vascular anomalous complexes in advanced age-related macular degeneration Ophthalmology 1996 103 2042 2053 9003338
   PubMed Web of Science ®Google Scholar
• Bottoni F Massacesi A Cigada M Viola F Musicco I Staurenghi G Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation Arch Ophthalmol 2005 123 1644 1650 16344434
   PubMed Web of Science ®Google Scholar
• Bressler NM Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease Arch Ophthalmol 2005 123 1741 1743 16344449
   PubMedGoogle Scholar
• Slakter JS Yannuzzi LA Schneider U Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration Ophthalmology 2000 107 742 753 discussion, 753–754 10768338
   PubMed Web of Science ®Google Scholar
• Kuroiwa US Arai J Gaun S Iida T Yoshimura N Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation Retina 2003 23 417 420 12824852
   PubMed Web of Science ®Google Scholar
• Sakimoto AS Gomi F Sakaguchi H Tano Y Recurrent retinal angiomatous proliferation after surgical ablation Am J Ophthalmol 2005 139 917 918 15860303
   PubMed Web of Science ®Google Scholar
• Shiragami C Iida T Nagayama D Baba T Shiraga F Recurrence after surgical ablation for retinal angiomatous proliferation Retina 2007 27 198 203 17290202
   PubMed Web of Science ®Google Scholar
• Boscia F Furino C Sborgia L Reibaldi M Sborgia C Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment Am J Ophthalmol 2004 138 1077 1079 15629318
   PubMed Web of Science ®Google Scholar
• Silva RM Cachulo ML Figueira J De Abreu JR Cunha-Vaz JG Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study Graefes Arch Clin Exp Ophthalmol 2007 245 1131 1139 17226019
   PubMed Web of Science ®Google Scholar
• Saito M Shiragami C Shiraga F Nagayama D Iida T Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation Am J Ophthalmol 2008 146 935 941 e1 18723139
   PubMed Web of Science ®Google Scholar
• Rouvas AA Papakostas TD Ntouraki A Douvali M Vergados I Ladas ID Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy Retina 2011 31 464 474 20948458
   PubMed Web of Science ®Google Scholar
• Shirakata Y Shiragami Y Shiragami C One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation Jpn J Ophthalmol 2012 56 599 607 22990616
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ Brown DM Heier JS Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006 355 1419 1431 17021318
   PubMed Web of Science ®Google Scholar
• Keane PA Liakopoulos S Ongchin SC Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 2008 49 3115 3120 18408176
   PubMed Web of Science ®Google Scholar
• Eghoj MS Sorensen TL Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 2012 96 21 23 21733918
   PubMed Web of Science ®Google Scholar
• Gasperini JL Fawzi AA Khondkaryan A Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation Br J Ophthalmol 2012 96 14 20 21791509
   PubMed Web of Science ®Google Scholar
• Forooghian F Chew EY Meyerle CB Cukras C Wong WT Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis Acta Ophthalmol 2011 89 e206 e207 19900197
   PubMed Web of Science ®Google Scholar
• Schaal S Kaplan HJ Tezel TH Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration Ophthalmology 2008 115 2199 2205 18930553
   PubMed Web of Science ®Google Scholar
• Swaroop A Chew EY Rickman CB Abecasis GR Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration Annu Rev Genomics Hum Genet 2009 10 19 43 19405847
   PubMed Web of Science ®Google Scholar
• Feng X Xiao J Longville B Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration Ophthalmology 2009 116 1908 1912 e1901 19692124
   PubMed Web of Science ®Google Scholar
• Brantley MA Fang AM King JM Tewari A Kymes SM Shiels A Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 2007 93 610 613
   Google Scholar
• Lee AY Raya AK Kymes SM Shiels A Brantley MA Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmology 2009 93 610 613
   PubMed Web of Science ®Google Scholar
• Chen H Yu KD Xu GZ Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis PLoS One 2012 7 8 e42464 10.1371/journal.pone.0042464 Epub 2012 8 14 22905135
   PubMed Web of Science ®Google Scholar
• Teper SJ Nowinska A Pilat J Palucha A Wylegala E Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis 2010 16 2598 2604 21151600
   PubMed Web of Science ®Google Scholar
• Orlin A Hadley D Chang W Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age related macular degeneration Retina 2012 32 4 9 21878851
   PubMed Web of Science ®Google Scholar
• Stewart MW Rosenfeld PJ Penha FM Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and afibercept (vascular endothelial growth factor trap-eye) Retina 2011 32 434 457 22374154
   PubMed Web of Science ®Google Scholar
• Lee SJ Koh HJ Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration Ophthalmology 2011 118 101 110 20678805
   PubMed Web of Science ®Google Scholar